Metastatic Urothelial Carcinoma

The FDA approved nivolumab in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic urothelial carcinoma, according to a press release.

MADRID — Remarkable. Highly meaningful. Monumental.

The addition of nivolumab to cisplatin-based chemotherapy improved outcomes compared with standard regimens for certain patients with advanced urothelial carcinoma, according to the agent’s manufacturer.

SAN FRANCISCO — Atezolizumab monotherapy improved OS compared with chemotherapy among patients with PD-L1-high, cisplatin-ineligible metastatic urothelial carcinoma, according to an exploratory analysis of a randomized phase 3 study.

SAN FRANCISCO — The addition of atezolizumab to platinum-based chemotherapy failed to significantly improve survival for patients with metastatic urothelial carcinoma, according to a final analysis of the randomized phase 3 IMvigor130 trial.

The FDA today granted approval to enfortumab vedotin-ejfv for treatment of adults with locally advanced or metastatic urothelial cancer.

Atezolizumab plus platinum-based chemotherapy prolonged PFS as first-line therapy for patients with metastatic urothelial carcinoma, according to results of the randomized phase 3 IMvigor130 trial published in The Lancet.

The FDA approved avelumab for the first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma, according to a press release from the manufacturer.

The combination of enfortumab vedotin and pembrolizumab conferred high rates of durable responses among cisplatin-ineligible patients with metastatic urothelial carcinoma, according to results of the multicohort EV-103 study.

The addition of maintenance avelumab to best supportive care extended OS for patients with previously untreated locally advanced or metastatic urothelial carcinoma, according to study results released by the agent’s manufacturer.